Plandai's Flagship Product Demonstrates Industry-Leading Efficacy in Killing Malaria Parasite

Marketwired

BALTIMORE, MD--(Marketwired - Jun 26, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that in a recently released independent study, Plandai Biotechnology Inc.'s (OTCQB: PLPL) flagship product demonstrated a twelve-times greater efficacy in killing the malaria parasite. This industry-leading performance may serve as a major boon to treating a disease which potentially impacts hundreds of millions of people and kills 600,000 in the African continent alone. Plandai is a developer of highly bioavailable, phytonutrient rich extracts (like EGCG), which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

Interestingly, the Company elected to use the complete Phytofare™ complex and not just the isolated EGCG (Epigallocatechin Gallate) catechin used in earlier studies. Clearly, these results show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial.

A key takeaway of these results is the notion that confirms Plandai's offerings provide the greatest efficacy of green tea catechins in the industry and this substantial antioxidant activity can potentially be formulated to treat and protect many other immune system conditions in addition to malaria.

To that end, management plans to complete a commercial delivery system by encapsulating Phytofare™ Catechin Complex into a proprietary nano-delivery system that is expected to deliver improved absorption and protection against gut metabolization, allowing super antioxidants to remain protected and intact until they reach the bloodstream.

In addition, further independent scientific investigations of Phytofare™ Catechin Complex in powder and nano-encapsulated forms will be undertaken both in vitro and in mouse models to validate the extract for oral consumption as an antimalarial drug target and in topical formulations for anti-aging and other applications as well.

With substantial absorption advantages, the innovative delivery system under development and the potential adaptability of its core offerings for the prevention and treatment of a multitude of conditions, Plandai is poised to serve as a supplier of the next generation of improved nutraceutical ingredients.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
View Comments (0)